<DOC>
	<DOCNO>NCT00071708</DOCNO>
	<brief_summary>The primary objective study provide duloxetine investigator treatment patient previously participate neuroscience duloxetine clinical trial effective alternative therapy available .</brief_summary>
	<brief_title>Duloxetine Compassionate Use Patients Who Have Completed Previous Neuroscience Duloxetine Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Male Female outpatient least 18 year age previously participate Lilly sponsor neuroscience duloxetine clinical trial All female must negative urine pregnancy test visit 1 . Females childbearing potential must agree utilize medically acceptable reliable mean birth control . Must sign inform consent document Have receive treatment within last 30 day drug except duloxetine receive regulatory approval indication time study entry In opinion investigator , patient judge serious suicidal risk . Serious unstable hepatic renal function unstable narrow angle glaucoma . Treatment monoamine oxidase inhibitor ( MAOI ) within 14 day prior visit 1 potential use MAOI study within 5 day discontinuation study drug . Any patient previously experience serious adverse event take duloxetine unless approve Lilly Physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>